Geraldino-Pardilla L, et al. - Researchers evaluated how hydroxychloroquine [HCQ: a key therapy in systemic lupus erythematosus (SLE)] levels are associated with disease activity in a predominantly Hispanic SLE cohort. From the Columbia University Lupus cohort, they included 108 SLE patients (median age: 38 years; 91% females; and 63% Hispanic) who were treated with HCQ for ≥ 6 months and had reported medication adherence. They noted an association of HCQ levels < 500 ng/ml with higher disease activity. These levels were identified accounting for 32% of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K: used to measure disease activity) variability. For assessing medication adherence in SLE, HCQ blood measurement is identified as a simple and reliable method.